MX2018006527A - Inhibidores de oligonucleotidos antisentido (aso) del transportador de monocarboxilato4 (mct4) para su uso como agentes terapeuticos en el tratamiento de cancer. - Google Patents
Inhibidores de oligonucleotidos antisentido (aso) del transportador de monocarboxilato4 (mct4) para su uso como agentes terapeuticos en el tratamiento de cancer.Info
- Publication number
- MX2018006527A MX2018006527A MX2018006527A MX2018006527A MX2018006527A MX 2018006527 A MX2018006527 A MX 2018006527A MX 2018006527 A MX2018006527 A MX 2018006527A MX 2018006527 A MX2018006527 A MX 2018006527A MX 2018006527 A MX2018006527 A MX 2018006527A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- mct4
- aso
- treatment
- therapeutics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260837P | 2015-11-30 | 2015-11-30 | |
| PCT/CA2016/000296 WO2017091885A1 (en) | 2015-11-30 | 2016-11-30 | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018006527A true MX2018006527A (es) | 2018-11-29 |
Family
ID=58795956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006527A MX2018006527A (es) | 2015-11-30 | 2016-11-30 | Inhibidores de oligonucleotidos antisentido (aso) del transportador de monocarboxilato4 (mct4) para su uso como agentes terapeuticos en el tratamiento de cancer. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10889814B2 (enExample) |
| EP (1) | EP3384028B1 (enExample) |
| JP (1) | JP7039470B2 (enExample) |
| CN (1) | CN108603194A (enExample) |
| AU (1) | AU2016363683B2 (enExample) |
| CA (1) | CA3006827A1 (enExample) |
| ES (1) | ES2893294T3 (enExample) |
| MX (1) | MX2018006527A (enExample) |
| WO (1) | WO2017091885A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017091885A1 (en) | 2015-11-30 | 2017-06-08 | The University Of British Columbia | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
| MX2019001389A (es) | 2019-01-31 | 2020-02-20 | Atso Corp Affairs S A De C V | Oligonucleotidos antisentido de las glutation s transferasa para el tratamiento del cancer. |
| EP3999117A4 (en) * | 2019-07-12 | 2023-07-26 | Duke University | NANOPARTICLE SYSTEMS FOR TARGETED CRISPR/CAS13 DELIVERY AND METHODS OF USE THEREOF |
| CN113197903B (zh) * | 2021-05-08 | 2022-01-07 | 江南大学 | 聚普瑞锌在制备用于治疗去势抵抗性前列腺癌药物中的应用 |
| WO2022250466A1 (ko) * | 2021-05-27 | 2022-12-01 | 사회복지법인 삼성생명공익재단 | 전립선암의 엔잘루타미드 저항성 억제용 약학 조성물 및 엔잘루타미드 저항성을 가지는 전립선암 치료용 약학 조성물 |
| CN113717971B (zh) * | 2021-08-10 | 2025-03-28 | 南通大学 | PGK1靶向siRNA干扰库及其应用 |
| CN114324870A (zh) * | 2021-12-22 | 2022-04-12 | 中国人民解放军空军军医大学 | 靶向髓系细胞乳酸转运信号的肺癌生物标志物和检测试剂盒 |
| CN114246829B (zh) * | 2021-12-31 | 2023-03-24 | 北京大学 | 一种反义核酸药物的包载方法、由该方法制备得到的药物制剂及其在肝癌治疗中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19832763A1 (de) | 1997-07-21 | 1999-03-18 | Schuster Christoph | Kraftfahrzeug mit einem verschließbaren Fahrerraum |
| NZ513757A (en) | 1999-02-26 | 2004-12-24 | Univ British Columbia | Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells |
| US20030059781A1 (en) * | 2000-03-21 | 2003-03-27 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer |
| US6637473B2 (en) | 2000-10-30 | 2003-10-28 | Robodesign International, Inc. | Automated storage and retrieval device and method |
| NZ538841A (en) | 2002-10-02 | 2006-10-27 | Univ British Columbia | Compositions for reducing hsp27 for the treatment of prostate and other cancers |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20050255114A1 (en) * | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| GB2407837B (en) | 2003-11-04 | 2007-07-11 | Corus Uk Ltd | Traffic control barriers |
| US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
| US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| US10570457B2 (en) | 2014-09-26 | 2020-02-25 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| WO2017091885A1 (en) | 2015-11-30 | 2017-06-08 | The University Of British Columbia | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
-
2016
- 2016-11-30 WO PCT/CA2016/000296 patent/WO2017091885A1/en not_active Ceased
- 2016-11-30 MX MX2018006527A patent/MX2018006527A/es unknown
- 2016-11-30 US US15/779,419 patent/US10889814B2/en active Active
- 2016-11-30 EP EP16869430.5A patent/EP3384028B1/en active Active
- 2016-11-30 CA CA3006827A patent/CA3006827A1/en active Pending
- 2016-11-30 CN CN201680069706.0A patent/CN108603194A/zh active Pending
- 2016-11-30 ES ES16869430T patent/ES2893294T3/es active Active
- 2016-11-30 AU AU2016363683A patent/AU2016363683B2/en active Active
- 2016-11-30 JP JP2018527863A patent/JP7039470B2/ja active Active
-
2020
- 2020-11-16 US US17/099,516 patent/US11466273B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2893294T3 (es) | 2022-02-08 |
| AU2016363683A1 (en) | 2018-07-12 |
| EP3384028A4 (en) | 2019-05-01 |
| WO2017091885A8 (en) | 2018-06-07 |
| US11466273B2 (en) | 2022-10-11 |
| CN108603194A (zh) | 2018-09-28 |
| AU2016363683B2 (en) | 2023-04-27 |
| EP3384028A1 (en) | 2018-10-10 |
| EP3384028B1 (en) | 2021-06-30 |
| US20190010492A1 (en) | 2019-01-10 |
| US10889814B2 (en) | 2021-01-12 |
| WO2017091885A1 (en) | 2017-06-08 |
| CA3006827A1 (en) | 2017-06-08 |
| JP2019500334A (ja) | 2019-01-10 |
| US20210395733A1 (en) | 2021-12-23 |
| JP7039470B2 (ja) | 2022-03-22 |
| BR112018011045A2 (pt) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017091885A8 (en) | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer | |
| FIC20250001I1 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| PH12020551195A1 (en) | Methods and compositions for macrophage polarization | |
| PH12018500719A1 (en) | Oligonucleotide compositions and methods thereof | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| NZ707477A (en) | Activin-actrii antagonists and uses for treating bone and other disorders | |
| NZ709635A (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| NZ601325A (en) | Compositions and methods for treating glioblastoma gbm | |
| MX2018005348A (es) | Composiciones y metodos para transduccion de tumores. | |
| HK1246230A1 (zh) | 人纤维肉瘤肝细胞癌(hfl-hccs) | |
| MX2020011415A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| PH12019502660A1 (en) | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE | |
| MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
| MX365392B (es) | Composición de combinación de pac-1 y doxorrubicina. | |
| MX2023000191A (es) | Metodos de fabricacion y uso de inhibidores de pde9. | |
| EP3781148A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID | |
| MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
| MX2020005344A (es) | Compuestos de pirazolopiridinona. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| WO2014028939A3 (en) | Targeting phosphofructokinase and its glycosylation form for cancer | |
| WO2019190927A3 (en) | Splice-switching oligonucleotides and methods of use | |
| HK1220356A1 (zh) | 用於前列腺癌的新颖疗法 |